Michelle Atchison, MD
Ophthalmology · Fargo, NDNPI 1659563039
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,383 of the $3,305 with a category attached, or 72.1%. 24 manufacturers reported payments, led by Alcon at 39.8% of the total. Reporting peaked in 2019 at $1,066 and has fallen 50.5% since, to $528 in 2025. Among ophthalmology clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 110 payments — averaging $30.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$1K
- Mallinckrodt Hospital Products Inc.$381
- AbbVie$247
- Amgen$206
- Dompe US, Inc.$164
- Sun Pharmaceutical Industries Inc.$149
- plus $842 from 18 others
What the payments were for
- Travel & lodging$71222%
- Food & beverage$2,38372%
- Education$1916%
- Gifts$191%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 23 | $1,316 |
| Mallinckrodt Hospital Products Inc. | 11 | $381 |
| AbbVie(2 entities) | 12 | $247 |
| Amgen(2 entities) | 10 | $206 |
| Dompe US, Inc. | 9 | $164 |
| Sun Pharmaceutical Industries Inc. | 8 | $149 |
| Oyster Point Pharma, Inc. | 4 | $89 |
| Genentech USA, Inc. | 4 | $88 |
| Novartis | 4 | $84 |
| Rxsight Inc | 2 | $77 |
| Astellas Pharma US Inc | 3 | $73 |
| Tarsus Pharmaceuticals, Inc. | 2 | $62 |
| The Cameron-ehlen Group, Inc. | 1 | $59 |
| Johnson & Johnson Vision Care, Inc. | 3 | $57 |
| Bausch & Lomb Americas Inc. | 2 | $39 |
| Glaukos Corporation | 2 | $35 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $35 |
| Aerie Pharmaceuticals, Inc. | 2 | $33 |
| Apellis Pharmaceuticals, Inc. | 1 | $21 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Harrow Eye, LLC | 1 | $17 |
| Biotissue Holdings Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,305 in reported general payments places this provider in the 90th percentile of 41 ophthalmology providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 39 | $47,306 |
| XdemvyLotilaner | 23 | $41,491 |
| XiidraLifitegrast | 20 | $26,173 |
| CombiganBrimonidine Tartrate/Timolol | 30 | $10,367 |
| Cyclosporine | 26 | $10,274 |
| RocklatanNetarsudil Mesylat/Latanoprost | 19 | $7,704 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,175 |
| Travoprost | 13 | $4,158 |
| Prednisolone Acetate | 77 | $3,804 |
| Alphagan PBrimonidine Tartrate | 13 | $3,476 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $3,433 |
| Latanoprost | 159 | $2,817 |
| Brimonidine Tartrate | 23 | $999 |
| Timolol Maleate | 80 | $902 |
| ErythromycinErythromycin Base | 54 | $650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan, Alphagan P | $247 | $61,14982 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $62 | $41,49123 claims |
| Bausch & Lomb Americas Inc.Xiidra | $39 | $26,17320 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $33 | $7,70419 claims |
| AlconSimbrinza | $1,316 | $4,17522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 ophthalmology providers in North Dakota.
Other ophthalmology in Fargo
- Lance BergstromFargo$10K
- Jennifer OlbumFargo$8K
- Anne KeatingFargo$3K
- Craig MasonFargo$3K
- Thomas StrindenFargo$3K
- Steven AndersonFargo$2K
- Michael GriessFargo$461
- David AndersonFargo$400
- Mariaha CobbFargo$310
- David GroszFargo$260
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.